Abstract
Prevention of sudden cardiac death is an important medical goal. Improved understanding of the natural history of a variety of cardiac conditions has increased the accuracy with which high risk patients can be identified and has emphasised the need for effective and non-toxic interventions. That ventricular fibrillation is probably the most common cause of death is supported by observations from out-of-hospital rescue squads and from continuous electrocardiographic tape recordings.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hampton JR. 1981. The use of beta blockers for the reduction of mortality after myocardial infarction. Eur Heart J 2: 2 59–68.
Campbell RWF, Murray A, Julian DG. 1981. Ventricular arrhythmias in the first twelve hours of acute myocardial infarction. Br Heart J 46: 351–7.
Horn HR, Hadidian Z, Johnson JL, Vassallo HG, Williams JH, Young MD. 1980. Safety evaluation in the American Emergency Use Program. Am Heart J100: 1037–40.
Goldberg R, Szklo M, Kennedy H, Tonascia J. 1978. Short and long-term prognosis of myocardial infarction complicated by ventricular fibrillation or cardiac arrest. Circulation 4(suppl 2):89(abs).
Geddes JS, Adgey AAJ, Pantrldge JF. 1969. Prognosis after recovery from ventricular fibrillation complicating ischaemic heart disease. Lancet 2: 273–5.
Eisenberg MS, Hallstrom A, Bergner L. 1982. Long-term survival after out-of-hospital cardiac arrest. New Eng. J Medicine 306: 1340–43.
Lie KI, Weilens HJJ, Durrer D. 1974. Characteristics and predictability of primary ventricular fibrillation. Eur J Cardiol 1: 379–84.
Valentine PA, Frew JL, Mashford ML, Sloman JG. 1974. Lidocaine in the prevention of sudden death in the pre¬hospital phase of acute infarction. New Eng J Med 291: 1327–31.
Lie KI, Liem KL, Louridtz WL, Janse MJ, Willebrands AF, Durrer D. 1978. Efficiency of lignocaine in preventing ventricular fibrillation within 1 hour after a 300mg intramuscular injection. A double blind randomised study of 300 hospitalised patients with acute myocardial infarction. Am J Cardiol 42: 486–8.
Koch-Weser J, Klein SW, Foo-Canto LL, Kastor JA, DeSanctis RW. 1969. Antiarrhythmic prophylaxis with procainamide in acute myocardial infarction. New Eng J Med 281: 1253–60.
Bloomfield SS, Romhilt DW, Chou T, Fowler NO. 1971. Quinidine for prophylaxis of arrhythmias in acute myocardial infarction. New Eng J Med 285: 979–86.
Campbell RWF, Achuff SC, Pottage A, Murray A, Prescott LF, Julian DG. 1979. Mexiletine in the prophylaxis of ventricular arrhythmias during acute myocardial infarction. J Cardio Pharm 1: 43–52.
Campbell RWF, Bryson LG, Bailey BJ, Murray A, Julian DG. 1979. Oral tocainide in suspected acute myocardial infarction. Circulation 59–60(suppl 2 ): 70 (abs).
Harrison DC. 1978. Should lidocaine be administered routinely to all patients after acute myocardial infarction? Circulation 58: 581–4.
Doubts about Lignocaine. 1975. Br Med J 1:473–4 (editorial).
The Norwegian Multicentre Study Group. 1981. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. 304: 801–7.
Hjalmarson A, Herlitz J, Malek I, Ryden L, Vedin A, Waldestrom A, Wedel H, Elmfeldt D, Holmberg S, Nyberg G, Swedberg K, Waagstein F, Waldenstrom J, Wilhelmsen L, Wilhelmsson C. 1981. Effect on mortality of metoprolol in acute myocardial infarction. A double blind randomised trial. Lancet 2: 823–7.
B-Blocker Heart Attack Trial Research Group. 1982. A randomised trial of propranolol in patients with acute myocardial infarction. JAMA 247: 1707–14.
Chamberlain DA, Jewitt DE, Julian DG, Campbell RWF, Boyle DMcC, Shanks RG. 1980. Oral mexiletine in high-risk patients after myocardial infarction. Lancet ii: 1324–7.
Van Durme JP, Hagemeijer F, Bogaert M. Glaser B, Hugenholtz PG. 1977. Chronic antidysrhythmic treatment after myocardial infarction. Design of the Gent-Rotterdam Aprindine Study. In Multicentre Controlled Trials: Principles and Problems, edited by Boissel JP, Klimt CR, Paris INSERM 76: 43.
Vaughan-Williams EM. 1978. Some factors that influence the activity of antiarrhythmic drugs. Br Heart J 40 (suppl): 52–61.
Heger JJ, Prystowsky EN, Jackman WM, Naccarelli GV, Warfel KA, Rinkenberger RL, Zipes DP. 1981. Amiodarone: clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. New Eng J Med 305: 539–44.
Myerburg RJ, Conde C, Sheps DS, Appel RA, Kiem I, Sung RJ, Castellanos A. 1979. Antiarrhythmic drug therapy in survivors of pre-hospital cardiac arrest: comparison of effects on chronic ventricular arrhythmias and recurrent cardiac arrest. Circulation 59: 855–63.
Schwartz PJ, Periti M, Malliani A. 1975. The Long QT syndrome. Am Heart J 89: 378–90.
May GS, Eberlein KA, Furberg CD, Passamani ER, DeMets DL. 1982. Secondary prevention after myocardial infarction: A review of long-term trials. Prog Cardiovasc Dis 24: 331–52.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Martinus Nijhoff Publishers, Boston
About this chapter
Cite this chapter
Campbell, R.W.F. (1983). Does Non Beta-Blocking Antiarrhythmic Therapy Prevent Sudden Cardiac Death?. In: Morganroth, J., Moore, E.N. (eds) Sudden Cardiac Death and Congestive Heart Failure: Diagnosis and Treatment. Developments in Cardiovascular Medicine, vol 25. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3876-5_15
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3876-5_15
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3878-9
Online ISBN: 978-1-4613-3876-5
eBook Packages: Springer Book Archive